Skip to main content

Table 2 Comparison of SSE incidence between groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Variable Denosumab (n = 120) ZA(n = 122) P - value
Total incidence of SSEs 10/120 21/122 0.04*a
SSE incidence
within 2 years 3/120 4/122 0.21a
after 2 years 7/120 17/122 0.04*a
  1. * Statistically significant values. aAnalysed using the Chi-square test. ZA: zoledronic acid; SSEs: symptomatic skeletal events